Alexander M. Lesokhin, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses safety results from the MagnetisMM-3 trial (NCT04649359), a Phase II, open-labeled, multicenter, non-randomized trial evaluating elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody in patients with relapsed/refractory multiple myeloma. Patients enrolled were refractory to at least 1 proteasome inhibitor, 1 immunomodulatory drug, and 1 anti-CD38 antibody. Preliminary results of MagnetisMM-3 in patients with relapsed/refractory myeloma and no prior BCMA-targeted treatment suggest that 76 mg of elranatamb adminstered once weekly with a 2-step-up priming regimen is well tolerated, with no grade 3 cytokine release syndrome or immune effector cell-assciated neurotoxicity syndrome (ICANS) observed. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
Noopur Raje, MD, Massachusetts General Hospital, Boston, MA, discusses recent advances in the use of antibodies for the treatment of multiple myeloma, highlighting the promise of monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), as well as bispecifics. Prof. Raje first comments on the movement of mAbs into the frontline setting and advances in quadruplet regimens. Following this, Prof. Raje highlights the DETERMINATION trial (NCT01208662), and further discusses the use of ADCs, such as belantamab mafodotin, as a single agent and in combination with other agents. To conclude, Prof. Raje discusses the promise of bispecific antibodies including teclistamab and elranatamab, and their place in the myeloma treatment landscape. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.